Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors Clinical Trial

Official title:

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02609737
• Other study ID #: 15-161
• Status: Completed
• Phase: N/A
• Start date: November 13, 2015
• Est. completion date: December 10, 2020

Study information

• Verified date: December 2020
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 10, 2020
• Est. primary completion date: December 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability to understand and the willingness to sign a written informed consent document

• Adults = 18 years old

• Histologically or cytologically confirmed metastatic and/or unresectable progressive, well differentiated carcinoid or pancreatic NET carcinoids

• Progressive metastatic disease defined by one of the following, occurring within 6 months of study entry:

• At least a 20% increase in radiologically or clinically measurable disease

• Appearance of any new lesion

• Symptomatic disease (including worsening hormonal symptoms or symptoms related to tumor burden)

• Measurable disease as defined by RECIST 1.1.

• At least one metastasis must show uptake of 111In-DTPA-octreotide on SPECT that is higher than the physiologic radiotracer uptake by the liver

• ECOG performance status = 2 (Karnofsky = 60%)

• Patients must have normal organ and marrow function as defined below:

• Leukocytes = 3.0 x 109/L

• Absolute neutrophil count (ANC) = 1.5 x 10^9/L

• Hemoglobin = 9.0 g/dL

• Platelets = 200 x 10^9/L

• Total bilirubin = 1.25 x Upper Limit Normal (ULN)

• AST (SGOT)/ ALT(SGPT) = 2.5 x ULN with liver metastases

• Alkaline phosphatase < 2 x ULN (if known liver or bone disease)

• Serum albumin > 30 g/L, or serum albumin = 30 g/L but normal prothrombin time

• Creatinine = 1.5 x ULN or creatinine clearance (CrCl) calculated CrCl = 60 mL/min/1.73m^2

• Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation

• Previous local therapy (e.g., chemoembolization or bland embolization) is allowed if completed > 6 weeks prior to study entry. For such patients, there must be either progression of measurable disease documented within the treatment field, or measurable progressive disease outside the treatment field prior to study entry.

• Previous chemotherapy and/or investigational agents are allowed if completed > 4 weeks prior to study entry (> 6 weeks if last regimen contained bis-chloroethyl nitrosourea (BCNU) or mitomycin C). For patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry.

• Patients must not have disease that is currently amenable to surgery. Prior surgery is allowed no less than 6 weeks prior to study entry.

Exclusion Criteria:

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-JR11 as assessed from medical records

• Life expectancy < 6 months as assessed by the treating physician.

• Treatment with short-acting somatostatin analogs less than 3 days and Sandostatin® depot injection less than 5 weeks before scanning and treatment

• Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Women who are pregnant or breastfeeding

• Toxicities from prior therapies that have not resolved to grade 1 or grade 0

• Known CNS metastases and/or carcinomatous meningitis

• Active malignancy of metastatic potential other than the known carcinoid or pancreatic NET within the past three years

• >20% bone marrow external beam radiotherapy and/or previous radioisotope therapy

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Device:
• PET/CT Imaging

Radiation:
• 68Ga-DOTA-JR11

• 177Lu-DOTA-JR11

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	according to RECIST 1.1 and median progression-free and overall survival will be estimated and reported with 95% confidence intervals	2 years

External Links

•   Memorial Sloan Kettering Cancer Center